NHS and Vertex remain deadlocked over price of cystic fibrosis drug

08 March 2019 – BMJ

Vertex Pharmaceuticals has been in dispute with NHS England over the high price the company wants for Orkambi—£105 000 (€123 000; $138 000) per patient per year. The Health and Social Care Committee’s inquiry received 334 written submissions, mostly from patients.

Jeff Leiden, Chief Executive Officer of Vertex Pharmaceuticals, told the committee he is meeting the health secretary Matt Hancock on 11.03.2019.


Ed. WEALTH WARNING – Neither I nor Brunswicks’ are licenced to give financial advice and nothing in this issue, or any other issue of Brunswicks’ Healthcare Review’ should be construed as advice, financial or otherwise, to anyone. Remember that the price of shares can fall as well as increase.

%d bloggers like this: